Cryoport, Inc. filings document the regulatory record for a Nasdaq-listed Nevada corporation providing temperature-controlled supply chain solutions to life sciences customers. Recent Form 8-K reports furnish quarterly and annual results releases, while definitive proxy materials describe governance matters, stockholder voting items and business updates tied to Life Sciences Services and Life Sciences Products.
The filing record also identifies Cryoport's registered common stock and recurring disclosure subjects such as operating performance, commercial and clinical cell and gene therapy support, biostorage and bioservices activity, cryogenic systems demand, executive and board governance, and stockholder meeting materials.
Cryoport, Inc. reports Q1 2026 results with total revenue of $47.8 million, up from $41.0 million a year earlier, driven by both services and products. Life Sciences Services contributed $26.9 million and Life Sciences Products $20.9 million.
The company recorded a loss from operations of $9.6 million versus $7.2 million last year, and a net loss of $10.5 million compared with $12.0 million. Net loss attributable to common stockholders was $12.5 million, or $0.25 per share, including a $2.0 million paid‑in‑kind dividend on Series C preferred stock.
Cryoport classified its former CRYOPDP courier business as discontinued operations following its 2025 divestiture and booked a $1.1 million loss from discontinued operations tied to an adjustment on the disposal. The company ended the quarter with $403.6 million in cash, cash equivalents and short‑term investments and generated $3.7 million of operating cash flow, while carrying $186.2 million of 0.75% Convertible Senior Notes due in 2026.
Cryoport, Inc. reported a strong start to 2026, with first-quarter revenue of $47.8 million, up 16% year-over-year. Life Sciences Services revenue rose to $26.9 million (up 18%), and Life Sciences Products reached $20.9 million (up 15%), driven by demand for cryogenic systems and integrated logistics.
Revenue supporting commercial cell and gene therapies grew 26% to $9.1 million, while clinical trial support revenue increased 18% to $12.9 million. The company supported 766 clinical trials as of March 31, 2026, including 91 in Phase 3 and 21 commercial therapies.
Despite growth, Cryoport posted a loss from continuing operations of $9.4 million and a net loss of $10.5 million, or -$0.25 per share, though adjusted EBITDA from continuing operations improved to -$0.6 million from -$2.8 million. Cash and cash equivalents were $272.9 million with $130.7 million in short-term investments, and full-year 2026 revenue guidance was raised to $192–$196 million.
Cryoport, Inc. President and CEO Jerrell Shelton exercised stock options to acquire 104,007 shares of common stock at $1.87 per share. These options, which vested monthly over four years beginning May 6, 2016, were fully exercised, leaving 0 options from this grant. After the transaction, Shelton directly holds 1,230,614 common shares, indicating an exercise-and-hold pattern with no same-day share sales reported.
Cryoport, Inc. is asking stockholders to approve six director nominees, ratify Deloitte & Touche as auditor, approve executive pay on an advisory basis, and amend its 2018 Omnibus Equity Incentive Plan to add 4,275,000 shares and extend the plan to the tenth anniversary of the 2026 meeting.
In 2025, Cryoport generated $176.2 million in revenue, up 12% year over year. Commercial Cell & Gene Therapy revenue rose to $33.4 million and clinical trial revenue to $47.1 million, while Life Sciences Services reached $96.5 million, about 55% of total revenue. Management forecasts 2026 revenue of $190–$194 million and highlights a growing pipeline of expected therapy approvals and regulatory filings.
Cryoport, Inc. President and CEO Jerrell Shelton exercised stock options and increased his direct share ownership. On the transaction date, he exercised options to purchase 50,000 shares of common stock at an exercise price of $1.87 per share, receiving 50,000 common shares.
Following the transactions, Shelton directly held 1,126,607 shares of Cryoport common stock and 104,007 options to purchase common stock. The exercised options were part of a grant that vested in equal 1/48 installments each month over forty-eight months beginning on May 6, 2016, with the options expiring on May 6, 2026.
CryoPort Inc — Schedule 13G/A (Amendment No. 7): The Vanguard Group reports zero shares beneficially owned of CryoPort Inc common stock, representing 0% of the class. The filing explains an internal realignment at The Vanguard Group on January 12, 2026, after which certain subsidiaries now report holdings separately.
Cryoport, Inc. Chief Financial Officer Robert Stefanovich reported a small, tax-related share sale. On this Form 4, he sold 1,094 shares of common stock at $8.18 per share, with a footnote stating the shares were required to be sold under company policy to pay taxes due upon the vesting of restricted stock rights. After the transaction, he directly holds 279,277 shares, indicating this was a routine withholding event tied to equity compensation rather than a discretionary reduction of his overall stake.
Cryoport, Inc. President and CEO Jerrell Shelton exercised stock options and completed a small share sale. He exercised options to acquire 25,000 shares of common stock at an exercise price of $1.87 per share. On the same date, he sold 2,894 shares of common stock at $8.18 per share.
According to the disclosure, the sold shares were required to be sold under company policies to pay taxes due upon the vesting of restricted stock rights, making this a tax-driven, rather than discretionary, sale. After these transactions, Shelton directly owned 1,076,607 shares of Cryoport common stock.
Cryoport, Inc. Chief Scientific Officer Mark W. Sawicki reported an automatic sale of 1,341 shares of common stock at $8.18 per share. According to the disclosure, the shares were required to be sold under company policies to pay taxes due upon the vesting of restricted stock rights. Following this transaction, Sawicki directly holds 102,356 shares of Cryoport common stock.